News

Latest news
April 14, 2026

The entrepreneur and mother of four shares her breast augmentation journey, from consultation to post-op, with Natrelle® breast implants. As a champion of authenticity, Lichy hopes her...

April 12, 2026

Results from the Phase 2 IMGN853-0420 trial show an objective response rate of 62.7% and consistent safety findings with mirvetuximab soravtansine-gynx (ELAHERE®) plus carboplatin followed by a...

April 08, 2026

NORTH CHICAGO, Ill., April 8, 2026 – As a longstanding participant in the 340B program, AbbVie believes the program’s original mission remains a noble one: to help safety-net hospitals and...

More »

AbbVie on

Looking for more news from AbbVie? Follow us on social media.

News

Advanced Search
Show 5102550100 per page
Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more

Sustainability

Our commitment to science is a commitment to better our society. Read our 2024 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more

Annual report

See our latest 2024 Annual Report on Form 10-K. Learn more

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?